NEULASTA
(Neulasta)ApprovedSmall molecule
AmgenNeulasta is used to help prevent infections in cancer patients undergoing chemotherapy by boosting the production of white blood cells. It reduces the risk of severe infections that can develop when chemotherapy lowers the body's infection-fighting cells.[2] NEULASTA is currently approved and in use across 3 indications[4].[1]
NEULASTA is one of 85 small molecule programs targeting Neutropenia. It is currently in Approved.
3
Indications
24
Total Trials
0
Active Trials
84
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Competition
Competitive Landscape
206 competitors in Lung Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Imfinzi
AstraZenecaPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Beyfortus
BeiGenePhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Imjudo
AstraZenecaPhase 3
Alunbrig
TakedaPhase 3
Ilaris
NovartisPhase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Tarlatamab-Dznl
AmgenPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Breast Cancer5 trials
Show 2 more trials
Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer
Completed·—·Phase 2·NCT02698891·127 enrolled
Efficacy and Safety3 trials
Neutropenia2 trials
12 more indications
Adult Subject1 trial
Lung Cancer1 trial
Neuropathy1 trial
The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy
Unknown status·—·Phase 1·NCT06168188·20 enrolled
Chemotherapy1 trial
Renal Cell Carcinoma1 trial
Urothelial Carcinoma1 trial
Carboplatin1 trial
Hodgkin Lymphoma1 trial
Regulatory
FDA Approval Timeline[5]
Jan 31, 2002
NEULASTA
BLA BLA125031
Sources
References
- [1]
- [2]MedlinePlus Drug Information — NEULASTA drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Neulasta. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]